Back to top
more

Bausch Health (BHC)

(Delayed Data from NYSE)

$8.48 USD

8.48
1,027,632

-0.28 (-3.20%)

Updated Nov 15, 2024 04:00 PM ET

After-Market: $8.48 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Bausch's (BHC) Arazlo Gets FDA Approval for Acne Vulgaris

by Zacks Equity Research

Bausch (BHC) gets FDA approval for Arazlo Lotion for the topical treatment of acne vulgaris in patients nine years of age or older.

Top Ranked Value Stocks to Buy for December 13

by Zacks Equity Research

Here are four stocks with buy rank and strong value characteristics for investors to consider today, December 13th

Are You Looking for a Top Momentum Pick? Why Bausch Health (BHC) is a Great Choice

by Zacks Equity Research

Does Bausch Health (BHC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is Bausch Health (BHC) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Why Is Bausch (BHC) Up 8.2% Since Last Earnings Report?

by Zacks Equity Research

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Bausch (BHC) Might be Well Poised for a Surge

by Zacks Equity Research

Bausch (BHC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Moving Average Crossover Alert: Bausch Health Companies

by Zacks Equity Research

Bausch Health Companies is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Indrajit Bandyopadhyay headshot

Generic Drugmakers Gain as Price-Fixing Probe Nears an End

by Indrajit Bandyopadhyay

Shares of generic drugmakers rose on Monday on a possible end to the persistent price-fixing probe.

Top Ranked Value Stocks to Buy for November 26th

by Zacks Equity Research

Here are four stocks with buy rank and strong value characteristics for investors to consider today, November 26th

Is Bausch Health (BHC) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Indrajit Bandyopadhyay headshot

Generic Drugs Industry Turns the Corner on Price Stabilization

by Indrajit Bandyopadhyay

Stabilizing prices of generic drugs are leading to recovery in the industry. New launches are also a boost. However, competition remains stiff.

Will Bausch Health Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Bausch Health.

Aerie (AERI) Q3 Loss Wider, Sales Beat, Guidance Slashed

by Zacks Equity Research

Aerie (AERI) posts a wider-than-expected Q3 loss and lowers guidance.

Is Bausch Health (BHC) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Bausch (BHC) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bausch (BHC) Beats on Q3 Earnings & Sales, Raises Guidance

by Zacks Equity Research

Bausch (BHC) beats on sales and earnings in the third quarter and raises annual guidance.

Bausch Health (BHC) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Bausch (BHC) delivered earnings and revenue surprises of 12.26% and 2.54%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Bausch Health (BHC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Bausch Health (BHC) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Bausch Health (BHC) stock based on the movements in the options market lately.

Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down

by Zacks Equity Research

Bausch's (BHC) shares down on lawsuit filed against Novartis' Sandoz defending Xifaxan patents.

Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa

by Zacks Equity Research

The CHMP recommends Aerie's (AERI) marketing application for Rhokiinsa to reduce elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.

Foamix Initiates Phase II Study on Acne Combination Foam

by Zacks Equity Research

Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.

Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment

by Zacks Equity Research

Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.

Why Is Bausch (BHC) Down 4.7% Since Last Earnings Report?

by Zacks Equity Research

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ardelyx (ARDX) Gains on Tenapanor's Success in Pivotal Study

by Zacks Equity Research

Ardelyx's (ARDX) lead pipeline candidate, tenapanor, meets primary endpoint in a pivotal phase III study.